Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy

Trends in Pharmacological Sciences

Volumn 38, Issue 1, 2017, Pages 15-24

  Deng, Xiaolan ^a   Nakamura, Yusuke ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

HLA; immunopharmacogenomics; liquid biopsy; neoantigen and shared antigen vaccine; personalized immunotherapy; TCR engineered T cells

Indexed keywords

CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SCREENING; CANCER THERAPY; CELL THERAPY; CHROMOSOME ABERRATION; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; NEOPLASM; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; TREND STUDY; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; BLOOD; DIAGNOSIS; EARLY CANCER DIAGNOSIS; GENETICS; IMMUNOTHERAPY; NEOPLASMS; TUMOR RECURRENCE;

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN P21;

DNA, NEOPLASM; EARLY DETECTION OF CANCER; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PHARMACOGENETICS; PRECISION MEDICINE; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 85006626463     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.10.013     Document Type: Review

References (72)

1. 1 Collins, F.S., Varmus, H., A new initiative on precision medicine. N. Engl. J. Med. 372 (2015), 793–795.
2. 2 Ashley, E.A., The precision medicine initiative: a new national effort. JAMA 313 (2015), 2119–2120.
3. 3 Cyranoski, D., China embraces precision medicine on a massive scale. Nature 529 (2016), 9–10.
4. 4 Aelion, C.M., et al. The US Cancer Moonshot initiative. Lancet Oncol. 17 (2016), 178–180.
5. 5 Kaiser, J., Couzin-Frankel, J., Biden seeks clear course for his Cancer Moonshot. Researchers have plenty of ideas for the Vice President's bid to boost collaboration and improve treatments. Science 351 (2016), 325–326.
6. 6 Friedman, A.A., et al. Precision medicine for cancer with next-generation functional diagnostics. Nat. Rev. Cancer 15 (2015), 747–756.
7. 7 Blumenthal, G.M., et al. Next-generation sequencing in oncology in the era of precision medicine. JAMA Oncol. 2 (2016), 13–14.
8. 8 Damodaran, S., et al. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. Am. Soc. Clin. Oncol. Educ. Book, 2015, 175–182.
9. 9 Errico, A., Genetics: clonal and subclonal events in cancer evolution – optimizing cancer therapy. Nat. Rev. Clin. Oncol., 12, 2015 372-372.
10. 10 Togneri, F.S., et al. Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Eur. J. Hum. Genet. 24 (2016), 1167–1174.
11. 11 Xia, Y., et al. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget 7 (2016), 35818–35831.
12. 12 Kato-Hayashi, N., et al. Use of cell-free circulating schistosome DNA in serum, urine, semen, and saliva to monitor a case of refractory imported schistosomiasis hematobia. J. Clin. Microbiol. 51 (2013), 3435–3438.
13. 13 Crowley, E., et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10 (2013), 472–484.
14. 14 Ray, K., Colorectal cancer: liquid biopsy enables real-time monitoring of molecular alterations in CRC. Nat. Rev. Gastroenterol. Hepatol., 12, 2015 372-372.
15. 15 Joosse, S.A., Pantel, K., Tumor-educated platelets as liquid biopsy in cancer patients. Cancer Cell 28 (2015), 552–554.
16. 16 Murtaza, M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497 (2013), 108–112.
17. 17 Romero, D., Breast cancer: tracking ctDNA to evaluate relapse risk. Nat. Rev. Clin. Oncol., 12, 2015 624-624.
18. 18 Sidaway, P., Urological cancer: genetics of mCRPC tracked in ctDNA. Nat. Rev. Clin. Oncol., 13, 2016 398-398.
19. 19 Sidaway, P., Prostate cancer: genetics of mCRPC tracked in ctDNA. Nat. Rev. Urol., 13, 2016 369-369.
20. 20 Rosell, R., Karachaliou, N., Lung cancer using ctDNA to track EGFR and KRAS mutations in advanced-stage disease. Nat. Rev. Clin. Oncol. 13 (2016), 401–402.
21. 21 Sausen, M., et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat. Commun. 6 (2015), 7686–7691.
22. 22 Taly, V., et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 59 (2013), 1722–1731.
23. 23 Thierry, A.R., et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 20 (2014), 430–435.
24. 24 Santiago-Walker, A., et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin. Cancer Res. 22 (2016), 567–574.
25. 25 Bettegowda, C., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6 (2014), 224–234.
26. 26 Alix-Panabieres, C., Pantel, K., Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6 (2016), 479–491.
27. 27 Heitzer, E., et al. Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 61 (2015), 112–123.
28. 28 Tie, J., et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8 (2016), 346–392.
29. 29 Garcia-Murillas, I., et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7 (2015), 302–312.
30. 30 Gevensleben, H., et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin. Cancer Res. 19 (2013), 3276–3284.
31. 31 Aparicio, S., Caldas, C., The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368 (2013), 842–851.
32. 32 Gardiner, R.A., et al. Integrating molecular profiling of liquid biopsy samples with a calculator algorithm to setect high-risk prostate cancer. Eur. Urol., 2016, 10.1016/j.eururo.2016.05.012 Published online May 24, 2016.
33. 33 Ignatiadis, M., Dawson, S.J., Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?. Ann. Oncol. 25 (2014), 2304–2313.
34. 34 Hodgkinson, C.L., et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat. Med. 20 (2014), 897–903.
35. 35 Hertz, D.L., Rae, J., Pharmacogenetics of cancer drugs. Annu. Rev. Med. 66 (2015), 65–81.
36. 36 Miller, V.A., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol. 13 (2012), 528–538.
37. 37 Paez, J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
38. 38 Shaw, A.T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368 (2013), 2385–2394.
39. 39 Anon., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med., 373, 2015, 1582.
40. 40 Solomon, B.J., et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J. Clin. Oncol. 34 (2016), 2858–2865.
41. 41 Schwaederle, M., et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol., 2016, 10.1001/jamaoncol.2016.2129 Published online June 6, 2016.
42. 42 Kiyotani, K., et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res. Treat. 131 (2012), 137–145.
43. 43 Kiyotani, K., et al. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J. Hum. Genet. 58 (2013), 327–333.
44. 44 Nakamura, Y., Immunopharmacogenomics. 2015, Springer.
45. 45 Andrews, A., Treating with checkpoint inhibitors – figure $1 million per patient. Am. Health Drug Benefits, 8, 2015, 9.
46. 46 Choudhury, N., Nakamura, Y., Importance of immunopharmacogenomics in cancer treatment: patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 107 (2016), 107–115.
47. 47 Zou, W., et al. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8 (2016), 328–341.
48. 48 Inoue, H., et al. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology, 5, 2016, e1204507.
49. 49 Ibrahim, R.A., et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J. Clin. Oncol., 29(Suppl.), 2011 abstr 8583.
50. 50 Teply, B.A., Lipson, E.J., Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology 3 (2014), 30–38.
51. 51 Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
52. 52 Hazama, S., et al. A Phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J. Transl. Med. 12 (2014), 63–73.
53. 53 Yoshitake, Y., et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin. Cancer Res. 21 (2015), 312–321.
54. 54 Suzuki, H., et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J. Transl. Med. 11 (2013), 97–106.
55. 55 Okuno, K., et al. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer. Anticancer Res. 34 (2014), 3045–3052.
56. 56 Hazama, S., et al. A Phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J. Transl. Med. 12 (2014), 108–117.
57. 57 Kono, K., et al. Multicenter, Phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer–testis antigens. J. Transl. Med. 10 (2012), 141–149.
58. 58 Iinuma, H., et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J. Transl. Med. 12 (2014), 84–95.
59. 59 Strønen, E., et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352 (2016), 1337–1341.
60. 60 Cohen, C.J., et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125 (2015), 3981–3991.
61. 61 Grupp, S.A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
62. 62 Lee, D.W., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a Phase I dose-escalation trial. Lancet 385 (2015), 517–528.
63. 63 Maude, S.L., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
64. 64 Davila, M.L., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6 (2014), 224–233.
65. 65 Porter, D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
66. 66 Jackson, H.J., et al. Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13 (2016), 370–383.
67. 67 Klebanoff, C.A., et al. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22 (2016), 26–36.
68. 68 Lee, D.W., et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195.
69. 69 Rapoport, A.P., et al. NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21 (2015), 914–921.
70. 70 Morgan, R.A., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
71. 71 Bonifant, C.L., et al. Toxicity and management in CAR T-cell therapy. Mol. Ther. Oncolytics 3 (2016), 16011–16018.
72. 72 Leisegang, M., et al. Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation. Clin. Cancer Res. 22 (2016), 2734–2743.